DermTech is a molecular diagnostic company developing and marketing non-invasive genomics tests to aid in the diagnosis and management of various skin conditions, including skin cancer, inflammatory diseases, and aging-related conditions. Co.'s focus is skin cancer. Co. provides the DermTech Melanoma Test for the early detection of melanoma and is developing a product for non-melanoma skin cancer. Co. is also working on products to assess precancerous genomic changes associated with sun UV exposure to the skin. Co. has additional skin cancer product offerings, including for non-melanoma skin cancers (basal cell and squamous cell cancers), under development. The DMTK YTD return is shown above.
The YTD Return on the DMTK YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether DMTK YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the DMTK YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|